Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly

Journal of Medicinal Chemistry

Volumn 57, Issue 14, 2014, Pages 6043-6059

  Chow, Mun Juinn ^a,b   Licona, Cynthia ^c,d   Yuan Qiang Wong, Daniel ^a   Pastorin, Giorgia ^a,b   Gaiddon, Christian ^c,d   Ang, Wee Han ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSERM   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 QUINOLINYLMETHYLENE 4 AMINOPHENOL; 4 METHOXY N (2 QUINOLINYLMETHYLENE)ANILINE; ANTINEOPLASTIC AGENT; N (2 PYRIDYLMETHYLENE) 1 NAPHTHYLAMINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROTEIN P53; RUTHENIUM DERIVATIVE; SCHIFF BASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CELL CYCLE; CHEMICAL STRUCTURE; COLORECTAL CANCER; COMBINATORIAL CHEMISTRY; DNA BINDING; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MOLECULAR WEIGHT; OVARY CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MCF-7 CELLS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; RUTHENIUM; SCHIFF BASES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; WATER;

EID: 84904977324     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500455p     Document Type: Article

References (62)

1. Dobson, C. M. Chemical Space and Biology Nature 2004, 432, 824-828
2. Lipinski, C.; Hopkins, A. Navigating Chemical Space for Biology and Medicine Nature 2004, 432, 855-861
3. Koch, M. A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting Biologically Relevant Chemical Space Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 17272-17277
4. Lipkus, A. H.; Yuan, Q.; Lucas, K. H.; Funk, S. A.; Bartelt, W. F. I.; Schenck, R. J.; Trippe, A. J. Structural Diversity of Organic Chemistry. A Scaffold Analysis of the CAS Registry J. Org. Chem. 2008, 73, 4443-4451
5. Bemis, G. W.; Murcko, M. A. The Properties of Known Drugs. 1. Molecular Frameworks J. Med. Chem. 1996, 39, 2887-2893
6. Meggers, E. Targeting Proteins with Metal Complexes Chem. Commun. 2009, 9, 1001-1010
7. Daniel, C. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA; Princeton Unversity Press: Princeton, NJ, 2010
8. Kelland, L. The Resurgence of Platinum-based Cancer Chemotherapy Nat. Rev. Cancer 2007, 7, 573-584
9. Clarke, M. J.; Zhu, F.; Frasca, D. R. Non-Platinum Chemotherapeutic Metallopharmaceuticals Chem. Rev. 1999, 99, 2511-2533
10. Rademaker-Lakhai, J. M.; van den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. Phase I and Pharmacological Study with Imidazolium- trans -DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Clin. Cancer Res. 2004, 10, 3717-3727
11. Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019, A New Redox-Active Anticancer Agent-Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients Chem. Biodiversity 2008, 5, 2140-2155
12. Hartinger, C. G.; Metzler-Nolte, N.; Dyson, P. J. Challenges and Opportunities in the Development of Organometallic Anticancer Drugs Organometallics 2012, 31, 5677-5685
13. Peacock, A. F.; Sadler, P. J. Medicinal Organometallic Chemistry: Designing Metal Arene Complexes as Anticancer Agents Chem.-Asian J. 2008, 3, 1890-1899
14. Nowak-Sliwinska, P.; van Beijnum, J. R.; Casini, A.; Nazarov, A. A.; Wagnieres, G.; van den Bergh, H.; Dyson, P. J.; Griffioen, A. W. Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity J. Med. Chem. 2011, 54, 3895-3902
15. Romero-Canelon, I.; Salassa, L.; Sadler, P. J. The Contrasting Activity of Iodido Versus Chlorido Ruthenium and Osmium Arene Azo- and Imino-pyridine Anticancer Complexes: Control of Cell Selectivity, Cross-Resistance, p53 Dependence, and Apoptosis Pathway J. Med. Chem. 2013, 56, 1291-1300
16. Nazarov, A. A.; Hartinger, C. G.; Dyson, P. J. Opening the Lid on Piano-Stool Complexes: An Account of Ruthenium(II)-Arene Complexes with Medicinal Applications J. Organomet. Chem. 2014, 751, 251-260
17. Paira, P.; Chow, M. J.; Venkatesan, G.; Kosaraju, V. K.; Cheong, S. L.; Klotz, K.; Ang, W. H.; G, P. Organoruthenium Antagonists of Human A3 Adenosine Receptors Chem.-Eur. J. 2013, 19, 8321-8330
18. Ong, J. X.; Yap, C. W.; Ang, W. H. Rational Design of Selective Organoruthenium Inhibitors of Protein Tyrosine Phosphatase 1B Inorg. Chem. 2012, 51, 12483-12492
19. Blanck, S.; Cruchter, T.; Vultur, A.; Riedel, R.; Harms, K.; Herlyn, M.; Meggers, E. Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors Organometallics 2011, 30, 4598-4606
20. Ang, W. H.; Casini, A.; Sava, G.; Dyson, P. J. Organometallic Ruthenium-Based Antitumor Compounds with Novel Modes of Action J. Organomet. Chem. 2011, 696, 989-998
21. Bergamo, A.; Masi, A.; Peacock, A. F.; Habtemariam, A.; Sadler, P. J.; Sava, G. In Vivo Tumour and Metastasis Reduction and in Vitro Effects on Invasion Assays of the Ruthenium RM175 and Osmium AFAP51 Organometallics in the Mammary Cancer Model J. Inorg. Biochem. 2010, 104, 79-86
22. Schmid, W. F.; John, R. O.; Muhlgassner, G.; Heffeter, P.; Jakupec, M. A.; Galanski, M.; Berger, W.; Arion, V. B.; Keppler, B. K. Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy J. Med. Chem. 2007, 50, 6343-6355
23. Reetz, M. T. Combinatorial and Evolution-Based Methods in the Creation of Enantioselective Catalysts Angew. Chem., Int. Ed. 2001, 40, 284-310
24. Francis, M. B.; Jamison, T. F.; Jacobsen, E. N. Combinatorial Libraries of Transition-Metal Complexes, Catalysts and Materials Curr. Opin. Chem. Biol. 1998, 2, 422-428
25. Mulcahy, S. P.; Grundler, K.; Frias, C.; Wagner, L.; Prokop, A.; Meggers, E. Discovery of a Strongly Apoptotic Ruthenium Complex Through Combinatorial Coordination Chemistry Dalton Trans. 2010, 39, 8177-8182
26. Robillard, M. S.; Bacac, M.; van den Elst, H.; Flamigni, A.; van der Marel, G. A.; van Boom, J. H.; Reedijk, J. Automated Parallel Solid-Phase Synthesis and Anticancer Screening of a Library of Peptide-Tethered Platinum(II) Complexes J. Comb. Chem. 2003, 5, 821-825
27. Robillard, M. S.; van Alphen, S.; Meeuwenoord, N. J.; Jansen, B. A. J.; van der Marel, G. A.; van Boom, J. H.; Reedijk, J. Solid-phase Synthesis of Peptide-Platinum Complexes Using Platinum-Chelating Building Blocks Derived From Amino Acids New J. Chem. 2005, 29, 220
28. Patra, M.; Hess, J.; Konatschnig, S.; Spingler, B.; Gasser, G. Synthesis of Ferrocenyl and Ruthenocenyl Thioamide Derivatives Using a Single-Step Three-Component Reaction Organometallics 2013, 32, 6098-6105
29. 2]: One-Pot Multicomponent Synthesis, DFT Study, and Synthetic Application Eur. J. Inorg. Chem. 2013, 2013, 415-426
30. Filak, L. K.; Goschl, S.; Heffeter, P.; Ghannadzadeh Samper, K.; Egger, A. E.; Jakupec, M. A.; Keppler, B. K.; Berger, W.; Arion, V. B. Metal-Arene Complexes with Indolo[3,2- c ]quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation Organometallics 2013, 32, 903-914
31. Zelonka, R. A.; Baird, M. C. Benzene Complexes of Ruthenium(II) Can. J. Chem. 1972, 50, 3063-3072
32. 2O Inorg. Chem. 1988, 27, 2554-2555
33. 6- p -Cymene Complexes of 3-Hydroxy-2(1 H)-pyridones J. Organomet. Chem. 2013, 734, 38-44
34. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a Tetrazolium-Based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing Cancer Res. 1987, 47, 936-942
35. Di, L.; Artursson, P.; Avdeef, A.; Ecker, G. F.; Faller, B.; Fischer, H.; Houston, J. B.; Kansy, M.; Kerns, E. H.; Kramer, S. D.; Lennernas, H.; Sugano, K. Evidence-based Approach To Assess Passive Diffusion and Carrier-Mediated Drug Transport Drug Discovery Today 2012, 17, 905-912
36. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches To Estimate Solubility and Permeability in Drug Discovery and Development Settings Adv. Drug Delivery Rev. 1997, 23, 3-25
37. Veber, D. F.; Johnson, S. R.; Cheng, H.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates J. Med. Chem. 2002, 45, 2625-2623
38. Test No. 107: Partition Coefficient (n-octanol/water): Shake Flask Method; OECD Publishing: Paris, 1995.
39. He, L.; Liao, S. Y.; Tan, C. P.; Ye, R. R.; Xu, Y. W.; Zhao, M.; Ji, L. N.; Mao, Z. W. Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies Chem.-Eur. J. 2013, 19, 12152-12160
40. Busto, N.; Valladolid, J.; Martinez-Alonso, M.; Lozano, H. J.; Jalon, F. A.; Manzano, B. R.; Rodriguez, A. M.; Carrion, M. C.; Biver, T.; Leal, J. M.; Espino, G.; Garcia, B. Anticancer Activity and DNA Binding of a Bifunctional Ru(II) Arene Aqua-Complex with the 2,4-Diamino-6-(2-pyridyl)-1,3,5-triazine Ligand Inorg. Chem. 2013, 52, 9962-9974
41. Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; Jodrell, D. I. In Vitro and in Vivo Activity and Cross Resistance Profiles of Novel Ruthenium (II) Organometallic Arene Complexes in Human Ovarian Cancer Br. J. Cancer 2002, 86, 1652-1657
42. Travnicek, Z.; Starha, P.; Popa, I.; Vrzal, R.; Dvorak, Z. Roscovitine-based CDK Inhibitors Acting as N-Donor Ligands in the Platinum(II) Oxalato Complexes: Preparation, Characterization and in Vitro Cytotoxicity Eur. J. Med. Chem. 2010, 45, 4609-4614
43. Zhang, S.; Lovejoy, K. S.; Shima, J. E.; Lagpacan, L. L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J. W.; Chen, X.; Lippard, S. J.; Giacomini, K. M. Organic Cation Transporters are Determinants of Oxaliplatin Cytotoxicity Cancer Res. 2006, 66, 8847-57
44. Meulmeester, E.; Jochemsen, A. G. p53-A Guide to Apoptosis Curr. Cancer Drug Targets 2008, 8, 87-97
45. Benosman, S.; Gross, I.; Clarke, N.; Jochemsen, A. G.; Okamoto, K.; Loeffler, J. P.; Gaiddon, C. Multiple Neurotoxic Stresses Converge on MDMX Proteolysis to Cause Neuronal Apoptosis Cell Death Differ. 2007, 14, 2047-2057
46. Boyer, J.; McLean, E. G.; Aroori, S.; Wilson, P.; McCulla, A.; Carey, P. D.; Longley, D. B.; Johnston, P. G. Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan Clin. Cancer Res. 2004, 10, 2158-2167
47. Brantley-Finley, C.; Lyle, C. S.; Du, L.; Goodwin, M. E.; Hall, T.; Szwedo, D.; Kaushal, G. P.; Chambers, T. C. The JNK, ERK and p53 Pathways Play Distinct Roles in Apoptosis Mediated by the Antitumor Agents Vinblastine, Doxorubicin, and Etoposide Biochem. Pharmacol. 2003, 66, 459-469
48. Chatterjee, S.; Kundu, S.; Bhattacharyya, A.; Hartinger, C. G.; Dyson, P. J. The Ruthenium(II)-Arene Compound RAPTA-C Induces Apoptosis in EAC Cells Through Mitochondrial and p53-JNK Pathways J. Biol. Inorg. Chem. 2008, 13, 1149-1155
49. Hayward, R. L.; Schornagel, Q. C.; Tente, R.; Macpherson, J. S.; Aird, R. E.; Guichard, S.; Habtemariam, A.; Sadler, P.; Jodrell, D. I. Investigation of the Role of Bax, p21/Waf1 and p53 as Determinants of Cellular Responses in HCT116 Colorectal Cancer Cells Exposed to the Novel Cytotoxic Ruthenium(II) Organometallic Agent, RM175 Cancer Chemother. Pharmacol. 2005, 55, 577-583
50. Vidimar, V.; Meng, X.; Klajner, M.; Licona, C.; Fetzer, L.; Harlepp, S.; Hebraud, P.; Sidhoum, M.; Sirlin, C.; Loeffler, J. P.; Mellitzer, G.; Sava, G.; Pfeffer, M.; Gaiddon, C. Induction of Caspase 8 and Reactive Oxygen Species by Ruthenium-derived Anticancer Compounds with Improved Water Solubility and Cytotoxicity Biochem. Pharmacol. 2012, 84, 1428-1436
51. Chin, C. F.; Tian, Q.; Setyawati, M. I.; Fang, W.; Tan, E. S.; Leong, D. T.; Ang, W. H. Tuning the Activity of Platinum(IV) Anticancer Complexes Through Asymmetric Acylation J. Med. Chem. 2012, 55, 7571-7582
52. Wang, F.; Habtemariam, A.; van der Geer, E. P.; Fernandez, R.; Melchart, M.; Deeth, R. J.; Aird, R.; Guichard, S.; Fabbiani, F. P.; Lozano-Casal, P.; Oswald, I. D.; Jodrell, D. I.; Parsons, S.; Sadler, P. J. Controlling Ligand Substitution Reactions of Organometallic Complexes: Tuning Cancer Cell Cytotoxicity Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 18269-18274
53. 2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): A Water Soluble Compound that Exhibits pH Dependent DNA Binding Providing Selectivity for Diseased Cells Chem. Commun. 2001, 15, 1396-1397
54. Aliende, C.; Perez-Manrique, M.; Jalon, F. A.; Manzano, B. R.; Rodriguez, A. M.; Cuevas, J. V.; Espino, G.; Martinez, M. A.; Massaguer, A.; Gonzalez-Bartulos, M.; de Llorens, R.; Moreno, V. Preparation of New Half Sandwich Ruthenium Arene Complexes with Aminophosphines as Potential Chemotherapeutics J. Inorg. Biochem. 2012, 117, 171-188
55. 4-Bonding in (Arene)ruthenium Complexes of Octamethylnapthalene Organometallics 1982, 3, 605-613
56. 6-Hexamethylbenzene)Ruthenium Complexes Inorg. Synth. 1982, 21, 74-78
57. Bennett, M. A.; Smith, A. K. Arene Ruthenium(II) Complexes Formed by Dehydrogenation of Cyclo-hexadienes with Ruthenium(III) Trichloride J. Chem. Soc., Dalton Trans. 1974, 223-241
58. SMART, version 5.628; Bruker AXS Inc.: Madison, WI, 2001.
59. SAINT +, version 6.22a; Bruker AXS Inc.: Madison, WI, 2001.
60. Sheldrick, G. W. SADABS, University of Gottingen: Gottingen, Germany, 2001.
61. SHELXTL, version 6.14; Bruker AXS Inc.: Madison, WI, 2000.
62. Quinn, P. J. Plasma Membrane Phospholipid Asymmetry Subcell. Biochem. 2002, 36, 1-25